Literature DB >> 8666372

Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection.

A D'Errico1, P Baccarini, M Fiorentino, C Ceccarelli, C Bonazzi, A Ponzetto, J Y Scoazec, A M Mancini, W F Grigioni.   

Abstract

To assess the utility of cytokeratin (CK) profile and albumin mRNA detection (as revealed by in situ hybridization) in the differential diagnosis of primary liver carcinomas (PLCs) we evaluated a series of surgically resected PLCs, comprising 20 "pure" hepatocellular carcinomas (HCCs) (10 well-differentiated, 10 poorly differentiated), 15 cholangiocarcinomas (CCs) (6 peripheral, 5 hilar, and 4 major duct ones) and 10 hepatocholangio-carcinomas (HCC-CCs). 11 of 20 (55%) of the pure HCCs expressed CKs of pure hepatocytic lineage (CK 8 and CK 18); 2 of 10 (20%) of the HCC-CCs displayed only hepatocytic profile, whereas 12 of 15 (80%) of the CCs evidenced mature bile duct cell phenotype (CK 8, CK 18, CK 7, CK 19). All HCCs expressed varying distributions of albumin mRNA, whereas 4 of 6 (67%) peripheral CCs showed cells with focal positivity for albumin mRNA. This suggests that the phenotypic expression of PLC cells are often not fixed, and in particular: (1) peripheral CCs have a different phenotype from hilar and large duct ones; (2) the CK profile and albumin mRNA expression in peripheral CCs show many similarities with those of some HCCs. Furthermore, the results show that a mixed biological phenotype (ie, CK 8, CK 18 and CK 7 and/or CK 19) can be found both among morphologically pure HCCs and peripheral CCs, suggesting that these two forms could share a common histogenesis. We think that special attention should be given to cases in which CK profile and albumin mRNA reveal mixed phenotype, as these tumors could have different biological behavior and respond differently to therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666372     DOI: 10.1016/s0046-8177(96)90169-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

2.  HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma.

Authors:  Abdelfattah M Attallah; Mohamed El-Far; Camelia A Abdel Malak; Mohamed M Omran; Gamal E Shiha; Khaled Farid; Lamiaa A Barakat; Mohamed S Albannan; Ahmed A Attallah; Mohamed A Abdelrazek; Mohamed S Elbendary; Refaat Sabry; Gehan A Hamoda; Mohamed M Elshemy; Abdallah A Ragab; Basma M Foda; Sanaa O Abdallah
Journal:  Tumour Biol       Date:  2015-05-01

Review 3.  Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress.

Authors:  Elizabeth M Brunt; Valerie Paradis; Christine Sempoux; Neil D Theise
Journal:  Hepat Oncol       Date:  2015-07-28

4.  Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.

Authors:  C Röcken; J Licht; A Roessner; S Carl-McGrath
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

5.  Modification of an in vivo lung metastasis model of hepatocellular carcinoma by low dose N-nitrosomorpholine and diethylnitrosamine.

Authors:  Hiroko Yoshino; Mitsuru Futakuchi; Young-Man Cho; Kumiko Ogawa; Fumitaka Takeshita; Norio Imai; Seiko Tamano; Tomoyuki Shirai
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation.

Authors:  Francesco Vasuri; Rita Golfieri; Michelangelo Fiorentino; Elisa Capizzi; Matteo Renzulli; Antonio D Pinna; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  Virchows Arch       Date:  2011-06-21       Impact factor: 4.064

7.  Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.

Authors:  Mohammad Shahid; Aysha Mubeen; Julie Tse; Sanjay Kakar; Adrian C Bateman; Darrell Borger; Miguel N Rivera; David T Ting; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

8.  Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas.

Authors:  Hiroya Iida; Masaki Hata; Ayako Kakuno; Hiroshi Hirano; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Nobuyuki Terada; Chiaki Yasui; Naoki Yamanaka; Keiji Nakasho
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

9.  Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells.

Authors:  Hee-Jung Yoo; Bo-Ra Yun; Jung-Hee Kwon; Hyuk-Soo Ahn; Min-A Seol; Mi-Jin Lee; Goung-Ran Yu; Hee-Chul Yu; BeeHak Hong; KwanYong Choi; Dae-Ghon Kim
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

10.  A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.

Authors:  Xiaoyong Fu; Lu Tan; Shuqin Liu; Honghai Li; Lei Chen; Jianmin Qin; Mengchao Wu; Hongyang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.